Annotation of HCSC Label for ropivacaine

Criteria Not MetLearn more about Label Annotation Levels of Evidence(opens in new window)

PharmGKB ID

PA166358981

Summary

The product monograph for ropivacaine (NAROPIN) contains no information about the risk of developing methemoglobinemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia (associated with variants in CYB5R3).

Annotation

Excerpt from the ropivacaine (NAROPIN) product monograph:

Ropivacaine is extensively metabolized in the liver predominantly to 3-hydroxy-ropivacaine by an aromatic hydroxylation process mediated by cytochrome P4501A2 and N-dealkylation to S-PPX mediated by CYP3A4.

For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the ropivacaine product monograph.

*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.

More information about drug label annotations on PharmGKB

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Source

    1. Drugs@HCSC: Drug Product NAROPIN (ropivacaine), Aspen Pharmacare Canada Inc
      Has No PGx

    History

    No history available.